26 research outputs found
Minimally invasive technologies for treatment of HTS and keloids : fractional laser
Hypertrophic fractional laser and keloid scars present a
spectrum of disorders that are difficult to treat. Multiple
treatments have been tried, to ameliorate the clinical
sequelae of scarring, such as erythema, pruritus, functional
limitation, reduced range of movement, dyschromias,
hyper and/or hypopigmentation. Early international
clinical recommendations on scar management first recognized
the importance of laser therapy in this armamentarium
[1]. Within the years that followed, laser technology
and the understanding of how it modulates the underlying
processes that leads to hypertrophic and keloid scarring
have experienced a quantum leap [2] and are still
evolving. Lasers also present a considerable financial
commitent, and it is possible, in the authors’ experience,
that limited early results partially stemmed from limited
availability of multiple lasers with consequent attempts to
overstretch the indications for what was available.
This chapter presents a state-of-the-art insight into
the use of fractional laser for the management of this
complex problem. In particular, we focus on the management
of complex scars such as those occurring post-burn
injury and split-thickness skin grafting.peer-reviewe
Recommended from our members
Indeterminate cell histiocytosis that presented clinically as benign cephalic histiocytosis
Indeterminate cell histiocytosis (ICH) is a rare, heterogeneous disorder that is characterized by immunophenotypic features of both Langerhans cell histiocytosis (LCH) and non-LCH. We describe a 12-month-old boy with a four-month history of asymptomatic, small, pink-tan papules on his face. Histopathologic evaluation showed a superficial, dermal infiltrate of histiocytes that was positive for S100, CD1a, CD68, and Factor XIIIa. To our knowledge, this represents the first report of the clinical presentation of benign cephalic histiocytosis with immunohistochemical findings of ICH. We review the classification of histiocytic disorders and the clinical and immunohistochemical features of both ICH and benign cephalic histiocytosis